Research and Markets: Daiichi Sankyo Pharmaceuticals is undertaking life-cycle management of the antihypertensive, Olmetec/Benicar, which is one of the companies main growth drivers.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c37586) has announced the addition of Daiichi Pharmaceutical Company Intelligence Report from Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. to their offering. Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices ap·pen·di·ces n. A plural of appendix. provide more in-depth information on financials, agreements and corporate events. For the nine months ended 31st December 2005, Daiichi Sankyo's net sales Net Sales The amount a seller receives from the buyer after costs associated with the sale are deducted. Notes: This amount is calculated by subtracting the following items from gross sales: merchandise returned for credit, allowances for damaged or missing goods, freight were 704,039 million Yen. Operating income Operating Income The profit realized from a business' own operations. Notes: This would not include income from things such as investments in other firms. Also referred to as operating profit or recurring profit. was 134,294 million Yen and net income was 80,992 million Yen. Research and development expenditure was 113,371 million Yen and pharmaceutical sales were 606,349 million Yen. Key products Daiichi Sankyo intends to maximise the value of its existing leading products, beyond what could have been achieved by the companies separately. For example: Daiichi Sankyo is undertaking life-cycle management of the antihypertensive antihypertensive /an·ti·hy·per·ten·sive/ (-ten´siv) counteracting high blood pressure, or an agent that does this. an·ti·hy·per·ten·sive adj. Reducing high blood pressure. n. , Olmetec/Benicar, which is one of the companies main growth drivers. Since its introduction in a number of markets, sales and market share are increasing. The future growth of the anti-infective an·ti-in·fec·tive adj. Capable of preventing or counteracting infection. n. An anti-infective agent or drug. anti-infective 1. counteracting infection. 2. a substance that counteracts infection. Cravit is expected to be strong due to life-cycle management efforts. In fiscal 2005, sales of the antihypertensive, Calblock, increased by 400%, to reach 3,000 million Yen and are forecast to exceed 10 billion Yen in Japan. Overseas pharmaceutical sales were negatively affected by the expiration EXPIRATION. Cessation; end. As, the expiration of, a lease, of a contract, or statute. 2. In general, the expiration of a contract puts an end to all the engagements of the parties, except to those which arise from the non- fulfillment of obligations created of the patent in certain European European emanating from or pertaining to Europe. European bat lyssavirus see lyssavirus. European beech tree fagussylvaticus. European blastomycosis see cryptococcosis. countries for pravastatin pravastatin /prav·a·stat·in/ (prav´ah-stat?in) an antihyperlipidemic agent that acts by inhibiting cholesterol synthesis, used as the sodium salt in the treatment of hypercholesterolemia and other forms of dyslipidemia and to lower the and increasing competition faced by that product in the US, which weakened weak·en tr. & intr.v. weak·ened, weak·en·ing, weak·ens To make or become weak or weaker. weak  en·er n. sales of bulk pravastatin. However, sales of olmesartan and
levofloxacin were strong.
Major Products Forecast to 2010 Cravit (Antibacterial) Omnipaque (Contrast agent) Panaldine (Cardiovascular) Artist (Cardiovascular) Sunrythm (Cardiovascular) Zyrtec (Anti-inflammatory) Mevalotin (Cardiovascular) Loxonin (Anti-infective) Remacin (Haematological) Acecol (Cardiovascular) Banan (Antibacterial) Espo (Haematological) Carbenin (Antibacterial) Gran (Anticancer) Alesion (Anti-allergenic) Olmetec (Cardiovascular) This company report provides: Latest Results A brief review of the latest report results Executive Summary At a glance understanding of the major trends and events affecting the company Financial Analysis (current year) Detailed P&L and investment review of the latest full year performance Company Strategy Where's the company going and how does it plan getting there? Product/R&D Pipeline Highly detailed monographs organised by therapeutic category. Also covers R&D strategy/pipeline and provides 5-year sales forecasts to 2010 for major launched products where available. Appendices 5-year financial assessment Key corporate events Key agreements Infrastructure Major pharmaceutical subsidiaries/joint ventures Product index Companies Mentioned Include: Kissei Pharmaceutical Co Ltd Kureha Chemical Industry Co Ltd Kyoto Pharmaceutical Industries Ltd Metabasis Therapeutics Inc Novartis Pfizer Pharmacopeia Inc Roche sanofi-aventis Sanwa Kagaku Kenkyusho Schering-Plough Suntory Ltd Teikoku Hormone Mfg Co Ltd Ube Industries Ltd University of Alabama Zeria Pharmaceutical Co Ltd For more information visit http://www.researchandmarkets.com/reports/c37586 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion